The Clinical Effectiveness of Ranibizumab Treat and Extend Regimen in nAMD: Systematic Review and Network Meta-Analysis
ConclusionThis study used novel repeated-measures NMA to synthesize efficacy results when treatment effects were reported at multiple follow-up times. This repeated-measures NMA suggests that treating patients with the ranibizumab T&E regimen yields similar effectiveness compared to other approved ranibizumab and aflibercept dosing regimens for nAMD treatment.Funding: Novartis Pharmaceuticals UK Ltd, Surrey, UK.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Age-Related Macular Degeneration (AMD) | Blindness | Diabetes | Drugs & Pharmacology | Endocrinology | Lucentis | Opthalmology | Ranibizumab Injection | Study